This text is a result of machine translation.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Pure Global: The International Engine of Medical Technology Globalization
As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.
Sep 28, 2023 09:30 AM
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Robust medical: it plans to acquire the controlling equity of Hunan Ping An medical equipment
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Yesterday 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Mask protection unit rose in the afternoon
Imber: the shareholder Ruan bin has completed the reduction of 337500 shares and plans to continue to reduce no more than 1.32% of the shares
Robust medical: by the end of October, 1159400 shares had been repurchased
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
Robust medical treatment: affected by the recent spread of delta virus strain, the company's demand for protective products such as masks and protective clothing has increased significantly